Navigation Links
ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012

RANCHO CORDOVA, Calif., May 7, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal third quarter ended March 31, 2012, on Thursday, May 10, 2012.

Company's Conference Call and Webcast

Management will host a conference call Thursday, May 10, 2012 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal third quarter financial results. 

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. Matthew T. Plavan, Chief Executive Officer and Chief Financial Officer will host the call to discuss the third quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins. 

To listen to the audio webcast of the call during or after the event, please visit:


A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site:
Contact: Investor Relations
+1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
2. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
3. ThermoGenesis Reports Second Quarter Fiscal 2012 Results
4. ThermoGenesis Provides Update on Res-Q® Clinical Evaluations at Leading Stem Cell Therapy Conference
5. Canadas First National Public Cord Blood Bank Adopts ThermoGenesis BioArchive Cryopreservation System
6. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
7. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
8. ThermoGenesis Corp. to Announce First Quarter Fiscal 2012 Results on November 10, 2011
9. ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao
Post Your Comments:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):